Industry

Deupirfenidone 825 mg TID slowed lung function decline in people with idiopathic pulmonary fibrosis (IPF) to the range expected of healthy older adults over 6 months; new, preliminary open-label extension data support durability of this treatment effect over at least 52 weeks Deupirfenidone 825 mg TID demonstrated a statistically significant benefit compared to placebo in … [Read more…]

Company’s NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3rd-generation EGFR inhibitors and outperforms other investigational 4th-generation inhibitors in a wide range of drug resistance models. MOUNT LAUREL, N.J.–(BUSINESS WIRE)–CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program … [Read more…]

With Cancer Rates in Women Under 50 now 82% Higher Than Men, Leading National Cancer Research and Treatment Organization Calls for Age-Specific Research, Expanded Risk Assessments, and Lifetime Survivorship Support LOS ANGELES–(BUSINESS WIRE)–City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical … [Read more…]

Report focuses on major themes of aligned growth, financial discipline, regulatory excellence, strategic agility, and talent optimization NEW YORK–(BUSINESS WIRE)–Healthcare executives are optimistic about future growth and financial performance, but they have concerns about regulatory and reimbursement restructuring as well as talent and workforce challenges, according to the Mindsets 2025 Healthcare Executive Leadership Report from … [Read more…]

ATLANTA–(BUSINESS WIRE)–Mirion Technologies, Inc. (“Mirion”) (NYSE: MIR), today announced its intent to offer $300.0 million aggregate principal amount of Convertible Senior Notes due 2030 (the “Notes”) in a private placement (the “Offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities … [Read more…]

High performance, sovereign and scalable cloud environment meets the highest standards for protecting sensitive health data Dassault Systèmes, through its OUTSCALE brand, addresses growing needs for health data security for processing and analysis Collaboration aligns with France’s 2025 public health priorities to structure and leverage complex clinical data within a sovereign and highly secure framework … [Read more…]

RevolKa gearing up AI-powered protein engineering to deliver novel therapeutics and engineered proteins SENDAI, Japan–(BUSINESS WIRE)–RevolKa Ltd. (RevolKa), a venture-backed biotech company providing a cutting-edge AI-driven protein engineering technology platform called aiProtein®, has raised 210 million JPY (US$1.4M) in Series A extension funding. This funding will advance RevolKa’s drug discovery programs for rare diseases (https://www.revolka.com/news/english/collab-en/a65) … [Read more…]

Twenty-seven thousand people united to fight cancer, fueling hope and discovery through record-setting attendance and fundraising SAN DIEGO–(BUSINESS WIRE)–#ConcertforCures—Curebound announced today that its 2025 Concert for Cures with global music icon and humanitarian Elton John raised $11.5 million in support of cancer research. The benefit concert, held at Petco Park, marks the largest and most … [Read more…]

PHOENIX–(BUSINESS WIRE)–Televeda, a community engagement platform dedicated to reducing social isolation and loneliness, has been awarded a contract by the U.S. Department of Veterans Affairs (VA) to pilot and expand its Hero’s Story Project (HSP), a culturally tailored suicide prevention program designed specifically for American Indian and Alaska Native (AIAN) veterans. The Hero’s Story Project … [Read more…]

AIRSUPRA demonstrated a 47% reduction in the risk of severe exacerbations in mild asthma compared with albuterol alone Full results published in the New England Journal of Medicine and presented at ATS 2025 International Conference WILMINGTON, Del.–(BUSINESS WIRE)–Positive full results from the BATURA Phase IIIb trial showed AstraZeneca’s anti-inflammatory reliever rescue therapy, AIRSUPRA (albuterol/budesonide), demonstrated … [Read more…]